US Pharma MarketingAcquiring VitalConnect could unlock a $1 billion cardiac monitoring market that is only partly served by iRhythm’s existing devices.
IRhythm grows heart monitoring leadership with $288M VitalConnect buy
IRhythm grows heart monitoring leadership with $288M VitalConnect buy is a pharma and life sciences industry update from MedTech Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: MedTech Dive